Edition:
United States

Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.79EUR
4:17am EDT
Change (% chg)

€0.01 (+1.28%)
Prev Close
€0.78
Open
€0.78
Day's High
€0.79
Day's Low
€0.78
Volume
46,050
Avg. Vol
291,321
52-wk High
€1.12
52-wk Low
€0.67

ALNEV.PA

Chart for ALNEV.PA

About

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company... (more)

Overall

Beta: 0.84
Market Cap(Mil.): €40.85
Shares Outstanding(Mil.): 52.38
Dividend: --
Yield (%): --

Financials

  ALNEV.PA Industry Sector
P/E (TTM): -- 213.75 15.85
EPS (TTM): -0.32 -- --
ROI: -271.64 -7.93 -8.31
ROE: -340.39 -9.29 -7.95

BRIEF-Neovacs announces FDA acceptance of new IND to expand Ifnalpha Kinoid clinical development program in dermatomyositis

* REG-NEOVACS ANNOUNCES FDA ACCEPTANCE OF A NEW IND TO EXPAND IN U.S. IFNALPHA KINOID CLINICAL DEVELOPMENT PROGRAM IN DERMATOMYOSITIS

Jul 19 2017

BRIEF-Neovacs syas phase IIb trial Ifnalpha Kinoid in Lupus gets positive IDSMB review

* REG-NEOVACS ANNOUNCES POSITIVE IDSMB REVIEW FOR PHASE IIB CLINICAL TRIAL OF IFNALPHA KINOID IN LUPUS

Jul 11 2017

BRIEF-Neovacs announces license agreement for Ifnalpha Kinoid for treatment of lupus in Turkey

* REG-NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNALPHA KINOID FOR TREATMENT OF LUPUS IN TURKEY

Jul 05 2017

BRIEF-Neovacs completes patient enrollment in phase IIb clinical study of IFNalpha kinoid

* NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNALPHA KINOID IN LUPUS

Jun 20 2017

BRIEF-Neovacs raises 3.7 million euros by issuing 4.6 million shares

* RAISES EUR 3.7 MILLION BY ISSUING 4.6 MILLION SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 01 2017

BRIEF-Neovacs to present clinical development update on ifnalpha kinoid in dermatomyosis

* Reg-Neovacs to present clinical development update on ifnalpha kinoid in dermatomyosis

May 04 2017

BRIEF-Neovacs FY operating loss widens to 17.3‍​ million euros

* FY revenue ‍​0.4 million euros versus 1.2 million euros ($1.29 million) year ago

Mar 30 2017

BRIEF-Neovacs and Biosense sign option agreement worth up to €65 million plus royalties

* Neovacs and Biosense sign option agreement worth up to €65 million plus royalties for Chinese development and commercial rights to ifnα kinoid for lupus and dermatomyositis

Feb 21 2017

BRIEF-Neovacs and Biosense sign option agreement worth up to 65 million euros

* And biosense sign option agreement worth up to 65 million euros ($68.80 million) plus royalties for Chinese development and commercial rights to Ifnalpha Kinoid for lupus and dermatomyositis

Feb 21 2017

BRIEF-Neovacs issued new broad patent in China for IFNalpha Kinoid

* Announced today that it has received notification of a new patent from the Chinese patent office

Feb 09 2017

Earnings vs. Estimates